About ProtoKinetix
Changing lives through cell survival
Watch
Watch
ProtoKinetix is a research and development company leading the way in cell survival solutions. AAGP®, our patented anti-aging glycopeptide, is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing.
Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide keeps more cells alive longer. It utilizes the same properties that help animals survive in arctic temperatures, and it has the capability to change regenerative medicine forever.
Our vision
With AAGP®, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve.
Key Milestones
- 2002
Public listing on open market - 2005
Initiation of pre-clinical type 1 diabetes research at the University of Alberta (Dr. James Shapiro) - 2006
Lead Scientist, Dr. Geraldine Deliencourt awarded prestigious Francinov medal for scientific excellence in the field of chemistry forming the basis of AAGP® - 2010
Good Manufacturing Practice processing established and preliminary toxicology assessment successful (with AmbioPharm) - 2014
Patent filing for type 1 diabetes with islet transplantation - 2015
Clarence Smith installed as Chief Executive Officer - 2016
Macular degeneration cell therapy program started at the University of British Columbia - 2016
Patent filing for macular degeneration with induced pluripotent stem cells - 2016
Preclinical validation of AAGP® in type 1 diabetes and peer-reviewed paper - 2016
Patent expanded for macular degeneration with induced pluripotent stem cells - 2016
Patent filing for macular degeneration with neurosensory precursor cells - 2017
Pre-clinical proof of concept for AAGP® in macular degeneration and peer-reviewed paper - 2017
Acquired approval from Health Canada for Phase-1a clinical trial type 1 diabetes using islet cell grafting (Dr. James Shapiro) - 2018
Enhanced biological production and hematopoietic stem cell recovery research program initiated at the University of British Columbia - 2018
Cardiovascular research program started at Dalhousie University (Dr. Thomas Pulinilkunnil) - 2019
Completed pre-clinical macular degeneration cell graft studies (Dr. Gregory Evans) - 2019
Completed pre-clinical ocular safety study in small animal (EyeCro) - 2019
Completed pre-clinical ocular safety study in large animal (Charles River) - 2019
Completed pre-clinical ocular efficacy study (EyeCro) - 2020
Acquired approval from Health Canada for Phase-1b clinical trial type 1 diabetes using islet cell grafting - 2020
Established partnership with IQVIA to execute go-forward strategy for dry eye disease clinical trial and commercialization program - 2020
Patent filing for AAGP® for use in dry eye disease - 2021
Pre-clinical validation of AAGP® in macular degeneration in peer-reviewed paper - 2021
Completion of eye drop formulation for validation studies
Research pipeline
We are moving cell survival forward by addressing the health conditions that affect our lives. See where we are today and where we are heading next.
Leadership team
The leaders at ProtoKinetix have a clear vision for the future of the company and for the future of regenerative medicine. Learn more about their backgrounds.
ProtoKinetix, Inc.